Screener / SEC EDGAR /CIK 0001368514 /10-K filed Feb 25, 2026, compared with Mar 18, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Biotechnology

Adma Biologics, Inc. ADMA

We are a U.S. based end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. 10-K, Item 1

Headquarters
Ramsey, NJ
CEO
Adam S. Grossman
Next results
around Jan 11, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $510.2M through the costs to a net profit of $146.9M · income statement of the 10-K

38% operating margin
Revenue to Gross profit: $292.8MRevenue to Cost of revenue: $217.4MGross profit to Operating profit: $191.4MGross profit to Operating expenses: $101.3MOperating profit to Net profit: $146.9MOperating profit to Tax & other: $44.5MOperating expenses to R&D: $4.8MOperating expenses to Sales, admin & other: $96.6M Revenue: $510.2M REVENUE $510.2M +20% Y/Y Gross profit: $292.8M · 57% margin GROSS PROFIT $292.8M 57% margin · +33% Y/Y Cost of revenue: $217.4M · 43% of revenue COST OF REVENUE $217.4M 43% of revenue Operating profit: $191.4M · 38% margin OPERATING PROFIT $191.4M 38% margin · +38% Y/Y Operating expenses: $101.3M · 20% of revenue OPERATING EXPENSES $101.3M 20% of revenue Net profit: $146.9M · 29% margin NET PROFIT $146.9M 29% margin · −26% Y/Y Tax & other: $44.5M · 9% of revenue TAX & OTHER $44.5M 9% of revenue R&D: $4.8M · 1% of revenue R&D $4.8M 1% of revenue Sales, admin & other: $96.6M · 19% of revenue SALES, ADMIN & OTHER $96.6M 19% of revenue
Gross profit $292.8M 57% margin · +33% Y/Y
Operating profit $191.4M 38% margin · +38% Y/Y
Net profit $146.9M 29% margin · −26% Y/Y
The full income statement, year by year

ADMA among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 19.6%, above 73% of 154 peers (their median 10.4%) REVENUE GROWTH 19.6% · above 73% Gross margin: 68.5%, above 63% of 107 peers (their median 63.4%) GROSS MARGIN 68.5% · above 63% Operating margin: 46.5%, above 98% of 138 peers (their median 9.8%) OPERATING MARGIN 46.5% · above 98% Net margin: 35.1%, above 97% of 153 peers (their median 6.7%) NET MARGIN 35.1% · above 97% FCF margin: 25.6%, above 90% of 144 peers (their median 9.9%) FCF MARGIN 25.6% · above 90% Return on capital: 24.3%, above 93% of 89 peers (their median 9.0%) RETURN ON CAPITAL 24.3% · above 93%
ADMA Peer median Below the median

What changed

10 new risk paragraphs and 4 accounting facts worth reading about. 10-K filed Feb 25, 2026 against Mar 18, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

4facts worth reading about the other 7 checks found nothing to note

  • Receivables growing faster than revenue
    Receivables +216.9% ($50.0M to $158.4M) vs revenue +19.6% ($426.5M to $510.2M), +197.2 pts apart
  • Cash from operations lower than net income
    Cash from operations $50.4M vs net income $146.9M (FY ending Dec 31, 2025)
  • Late filing notice (NT 10-K or NT 10-Q)
    NT 10-K filed Mar 3, 2025: the company said its 10-K would be late
  • Critical audit matters changed
    New this year: Sufficiency of audit evidence over inventory (“As disclosed in Notes 2 and 3 to the consolidated financial statements, the Company held $206.4 million of inventory as of December 31, 2025. Inventories are comprised of raw materials, work-in-process, and finished goods.”). No longer listed: Valuation of the U.S. Medicaid rebate accrual for immunoglobulin products
  • Inventory +21.3% ($170.2M to $206.5M) vs revenue +19.6% ($426.5M to $510.2M), +1.7 pts apart
6 more checks with nothing to note
  • Same auditor in both 10-Ks: KPMG LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

10 paragraphs in Risk Factors that were not in the 10-K filed Mar 18, 2025. Quoted as filed.

All 10 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Mar 18, 2025 10-K, ITEM 1A
    Issues in the development and use of AI may result in reputational harm and increased liability exposure.
  2. Item 1A · new paragraph · not in the 10-K filed Mar 18, 2025 10-K, ITEM 1A
    Our business may be adversely affected by a pandemic, epidemic, or outbreak of an unknown or emerging infections disease.
  3. Item 1A · new paragraph · not in the 10-K filed Mar 18, 2025 10-K, ITEM 1A
    Regulatory authorities may not accept data from foreign clinical studies or sites or may find that such data is not sufficiently representative of the population of the approving jurisdiction;
  4. Item 1A · new paragraph · not in the 10-K filed Mar 18, 2025 10-K, ITEM 1A
    On August 5, 2025 (the “JPM Closing Date”), we entered into a credit agreement with JPMorgan and certain other lenders party thereto (the “JPM Credit Agreement”) (see “Liquidity and Capital Resources”). The JPM Credit Agreement provides for a total of $300 million in senior secured credit facilities (the “JPM Credit Facilities”)…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$154.1M$258.2M$426.5M$510.2M
Net income−$65.9M−$28.2M$197.7M$146.9M
Operating cash flow−$59.5M$8.8M$118.7M$50.4M
Free cash flow−$73.4M$4.0M$110.4M$27.8M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$510.2M ▲ 19.6% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

3 filings in the last 30 days · SEC EDGAR

All filings

About the company

Adma Biologics, Inc., Ramsey, NJ · from the 10-K filed Feb 25, 2026

We are a U.S. based end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Our targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.

Headquarters
Ramsey, NJ
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 4, 2026
Incorporated in
DE

Email alerts

Sources

The 10-K filed Feb 25, 2026 (open at SEC), compared with the 10-K filed Mar 18, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ADMA/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.